Prostate cancer management and factors associated with radical prostatectomy in France in 2001;Le cancer de la prostate en France en 2001 : état des pratiques et facteurs associés à la réalisation d'une prostatectomie totale

Progres en Urologie

Volumn 20, Issue 1, 2010, Pages 56-64

  Jegu, J ^a,d   Tretarre, B ^b   Velten, M ^b   Guizard, A V ^b   Danzon, A ^b   Buemi, A ^b   Colonna, M ^b   Kadi Hanifi, A M ^b   Ganry, O ^b   Molinie, F ^b   Bara, S ^b   Rebillard, X ^c   Grosclaude, P ^a,b,d  

^a Registre des Cancers du Tarn   (France)

^b Francim ^*  (France)

^c Clinique Beausoleil   (France)

^d INSERM   (France)

Author keywords

Epidemiology; France; Prostatic Neoplasm; Prostatic Neoplasm therapy; Registries

Indexed keywords

ADULT; AGED; ARTICLE; FRANCE; HUMAN; MALE; MIDDLE AGED; PROSTATE TUMOR; PROSTATECTOMY; STATISTICS;

ADULT; AGED; AGED, 80 AND OVER; FRANCE; HUMANS; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 73849147926     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2009.09.004     Document Type: Article

References (14)

1. Soulie M., Villers A., Grosclaude P., Menegoz F., Schaffer P., Mace-Lesec'h J., et al. Le cancer de la prostate en France : résultats de l'enquête CCAFU-FRANCIM. Prog Urol 11 (2001) 478-485
2. Bauvin E., Soulie M., Menegoz F., Mace-Lesec'h J., Buemi A., Velten M., et al. Medical and non-medical determinants of prostate cancer management: a population-based study. Eur J Cancer 39 (2003) 2364-2371
3. Soulie M., Villers A., Grosclaude P., Menegoz F., Schaffer P., Mace-Lesec'h J., et al. A population-based study on radical prostatectomy in France. Prostate Cancer Prostatic Dis 4 (2001) 118-123
4. Soulie M., Grosclaude P., Villers A., Menegoz F., Schaffer P., Mace-Lesec'h J., et al. A population-based study on management of prostate cancer in four regions of France. Prostate Cancer Prostatic Dis 4 (2001) 154-160
5. Humphrey P.A. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 17 (2004) 292-306
6. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987) 373-383
7. D'Amico A.V., Whittington R., Malkowicz S.B., Weinstein M., Tomaszewski J.E., Schultz D., et al. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 166 (2001) 2185-2188
8. Harlan L.C., Potosky A., Gilliland F.D., Hoffman R., Albertsen P.C., Hamilton A.S., et al. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst. 93 (2001) 1864-1871
9. Konety B.R., Cowan J.E., and Carroll P.R. Patterns of primary and secondary therapy for prostate cancer in elderly men: analysis of data from CaPSURE. J Urol. 179 (2008) 1797-1803 [discussion 1803]
10. Post P.N., Kil P.J., Hendrikx A.J., Janssen-Heijnen M.L., Crommelin M.A., and Coebergh J.W. Comorbidity in patients with prostate cancer and its relevance to treatment choice. BJU Int 84 (1999) 652-656
11. Adolfsson J., Garmo H., Varenhorst E., Ahlgren G., Ahlstrand C., Andren O., et al. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol 41 (2007) 456-477
12. Villers A., Rebillard X., Soulie M., Davin J.L., Coloby P., Moreau J.L., et al. Le dépistage du cancer de prostate. Prog Urol 13 (2003) 209-214
13. Wilt T.J., MacDonald R., Rutks I., Shamliyan T.A., Taylor B.C., and Kane R.L. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 148 (2008) 435-448
14. Schroder F.H., Hugosson J., Roobol M.J., Tammela T.L., Ciatto S., Nelen V., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360 (2009) 1320-1328